ArticleSurgery today2024
The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer.
Article in Surgery today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria.Surgery today · 2026Article
- Adjuvant treatment after surgical resection of pancreatic cancer.Surgery today · 2026Review
- Recent advances in hydrogel-based delivery systems for the treatment of pancreatic cancer.Materials today. Bio · 2025Review
- Cachexia index as a prognostic marker in patients undergoing biliary tract cancer resection.Surgery today · 2025Article
- The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer.Surgery today · 2025Article
- Article
- Low prealbumin level is a poor prognostic biomarker for surgically treated pancreatic cancer.Molecular and clinical oncology · 2025Article
- Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer.In vivo (Athens, Greece)Article
- The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer cachexia leads to poor outcomes, especially for patients with advanced stage disease. The cachexia index (CXI), a novel biomarker for cancer cachexia, has been identified as a prognostic indicator for several malignancies. The present study aimed to clarify the prognostic significance of the CXI for patients with recurrent pancreatic cancer.
methodsThis retrospective study enrolled 113 patients diagnosed with recurrence following pancreatectomy for pancreatic cancer, to analyze the association between the CXI and prognostic survival.
resultsThe 2-year overall survival rate and median survival of all patients were 28.5% and 12.6 months, respectively. The 2-year overall survival curve in the high CXI group was significantly better than that in the low CXI group (p < 0.001). The rate of chemotherapy after recurrence was significantly lower in the low CXI group than in the high CXI group (p = 0.002). Multivariate analysis identified the CXI as an independent prognostic factor for patients with recurrent pancreatic cancer (p = 0.011).
conclusionsThe CXI proved useful for predicting the post-recurrence prognosis of patients with recurrent pancreatic cancer. Patients with a low CXI at the time of recurrence have poorer prognostic outcomes than those with a high CXI.
Indexed as
Identifiers
38822841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.